Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Hsp72 mediates stronger antigen-dependent non-classical MHC class Ib anti-tumor responses than hsc73 in Xenopus laevis.
Nedelkovska H
,
Robert J
.
???displayArticle.abstract???
The heat shock proteins (HSPs) gp96 and HSP70 mediate potent antigen-dependent anti-tumor T cell responses in both mammals and Xenopus laevis. We have shown that frogs immunized with total HSP70 generate CD8+ T cell responses against the Xenopus thymic lymphoid tumor 15/0 that expresses several non-classical MHC class Ib (class Ib) genes, but no classical MHC class Ia (class Ia). In the absence of class Ia, we hypothesized that hsp72 can prime class Ib-mediated anti-tumor unconventional CD8+ T cells in an antigen-dependent manner. To test this, we produced Xenopus recombinant HSP70 proteins (both the cognate hsc73 and the inducible hsp72) from stable 15/0 tumor transfectants. We used an in vivo cross-presentation assay to prime animals by adoptive transfer of HSP-pulsed antigen-presenting cells (APCs) and showed that both hsp72-and hsc73-Ag complexes have a similar potential to elicit class Ia-mediated T cell responses against minor histocompatibility (H) Agskin grafts. In contrast, our in vivo cross-presentation assay revealed that hsp72 was more potent than hsc73 in generating protective immune responses against the class Ia-negative 15/0 tumors in an Ag-dependent and class Ib-mediated manner. These results suggest that hsp72 can stimulate class Ib-mediated immune responses and represents a promising candidate for immunotherapy against malignancies with downregulated class Ia expression.
Arnall,
Impaired rejection of minor-histocompatibility-antigen-disparate skin grafts and acquisition of tolerance to thymus donor antigens in allothymus-implanted, thymectomized Xenopus.
1986, Pubmed,
Xenbase
Arnall,
Impaired rejection of minor-histocompatibility-antigen-disparate skin grafts and acquisition of tolerance to thymus donor antigens in allothymus-implanted, thymectomized Xenopus.
1986,
Pubmed
,
Xenbase
Asea,
HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine.
2000,
Pubmed
Asea,
Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4.
2002,
Pubmed
Basu,
Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway.
2000,
Pubmed
Bendz,
Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling.
2007,
Pubmed
Blachere,
Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity.
1997,
Pubmed
Bleicher,
Mitogenic responses of frog lymphocytes to crude and purified preparations of bacterial lipopolysaccharide (LPS).
1983,
Pubmed
,
Xenbase
Calderwood,
Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity.
2005,
Pubmed
Callahan,
Differential acquisition of antigenic peptides by Hsp70 and Hsc70 under oxidative conditions.
2002,
Pubmed
Castellino,
Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways.
2000,
Pubmed
Ciocca,
Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications.
2005,
Pubmed
Flajnik,
Immune responses of thymus/lymphocyte embryonic chimeras: studies on tolerance and major histocompatibility complex restriction in Xenopus.
1985,
Pubmed
,
Xenbase
Gomes,
Non-classical major histocompatibility complex proteins as determinants of tumour immunosurveillance.
2007,
Pubmed
Gong,
A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use.
2010,
Pubmed
Goyos,
Novel nonclassical MHC class Ib genes associated with CD8 T cell development and thymic tumors.
2009,
Pubmed
,
Xenbase
Goyos,
Anti-tumor MHC class Ia-unrestricted CD8 T cell cytotoxicity elicited by the heat shock protein gp96.
2004,
Pubmed
,
Xenbase
Johnson,
pXeX, a vector for efficient expression of cloned sequences in Xenopus embryos.
1994,
Pubmed
,
Xenbase
Kiang,
Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology.
1998,
Pubmed
Mosser,
Molecular chaperones and the stress of oncogenesis.
2004,
Pubmed
Ménoret,
Co-segregation of tumor immunogenicity with expression of inducible but not constitutive hsp70 in rat colon carcinomas.
1995,
Pubmed
Nedelkovska,
Comparative in vivo study of gp96 adjuvanticity in the frog Xenopus laevis.
2010,
Pubmed
,
Xenbase
Nicchitta,
Re-evaluating the role of heat-shock protein-peptide interactions in tumour immunity.
2003,
Pubmed
Rau,
MHC-restricted and -unrestricted CD8 T cells: an evolutionary perspective.
2001,
Pubmed
,
Xenbase
Robert,
Lymphoid tumors of Xenopus laevis with different capacities for growth in larvae and adults.
1994,
Pubmed
,
Xenbase
Robert,
Phylogenetic conservation of glycoprotein 96 ability to interact with CD91 and facilitate antigen cross-presentation.
2008,
Pubmed
,
Xenbase
Robert,
Phylogenetic conservation of the molecular and immunological properties of the chaperones gp96 and hsp70.
2001,
Pubmed
,
Xenbase
Robert,
Minor histocompatibility antigen-specific MHC-restricted CD8 T cell responses elicited by heat shock proteins.
2002,
Pubmed
,
Xenbase
Robert,
Evolution of heat shock protein and immunity.
2003,
Pubmed
,
Xenbase
Robert,
Xenopus as an experimental model for studying evolution of hsp--immune system interactions.
2004,
Pubmed
,
Xenbase
Srivastava,
Therapeutic cancer vaccines.
2006,
Pubmed
Srivastava,
Roles of heat-shock proteins in innate and adaptive immunity.
2002,
Pubmed
Zitvogel,
Cancer despite immunosurveillance: immunoselection and immunosubversion.
2006,
Pubmed
de Kruijf,
HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients.
2010,
Pubmed
